MRTX - Mirati Therapeutics EPS beats by $1.47 beats on revenue November, 08 2021 04:06 PM Mirati Therapeutics Inc. Mirati Therapeutics (NASDAQ:MRTX): Q3 GAAP EPS of -$1.55 beats by $1.47. Revenue of $71.8M (+529.8% Y/Y) beats by $70.39M. Press Release For further details see: Mirati Therapeutics EPS beats by $1.47, beats on revenue